Thanks Gary. One of the most common feedback was that our reports were not actionable enough, as it's hard for regular investors to replicate the strategies.
Advocates of efficient markets would say that these facts are known and already priced into the market for each stock. There are reasons both to believe that and not to believe it. I don't buy individual stocks - but I do appreciate the insights and quality of the argument that was made. So, not my cup of tea, but very well brewed just the same.
Any particular reason for the focus on only five years rather than 10 to 40 years? Viking's peptide patent does not seem to expire until 2043 and has the far more pessimistic current pricing of their shares.
1. There are a lot more players who will finish phase 3 trials in the next 5 years. We can always check in after a year or so to see if we should update the portfolio.
2. Most of the valuation calculations projects for the next 5 years and then assign a terminal valuation. It becomes harder to assign a growth rate if you need to project accurately for 20 years.
I was surprised that you provided a 12 stock suggested portfolio. This is rare. Overall I was quite impressed with this presentation.
Thanks Gary. One of the most common feedback was that our reports were not actionable enough, as it's hard for regular investors to replicate the strategies.
This way, it's much more accessible to everyone.
Great read, excellent work, Thanks!
Thanks Tim
Nice thesis and analysis! Thanks for sharing 👌
Thank you.
Advocates of efficient markets would say that these facts are known and already priced into the market for each stock. There are reasons both to believe that and not to believe it. I don't buy individual stocks - but I do appreciate the insights and quality of the argument that was made. So, not my cup of tea, but very well brewed just the same.
Haha. Well put.
We will have a healthy mix of both styles of articles starting now :)
Any particular reason for the focus on only five years rather than 10 to 40 years? Viking's peptide patent does not seem to expire until 2043 and has the far more pessimistic current pricing of their shares.
2 reasons.
1. There are a lot more players who will finish phase 3 trials in the next 5 years. We can always check in after a year or so to see if we should update the portfolio.
2. Most of the valuation calculations projects for the next 5 years and then assign a terminal valuation. It becomes harder to assign a growth rate if you need to project accurately for 20 years.